Preparation of an oral pharmaceutical formulation containing an anti-infective agent and a microorganism

• US 6,306,391 B1
• Filed: 03/23/1998
• Issued: 10/23/2001
• Est. Priority Date: 03/27/1997
• Status: Expired due to Fees

• Current Assignee: Cadila Pharmaceuticals Limited (Rajiv Indravadan Modi, PhD)
• Original Assignee: Cadila Pharmaceuticals Limited (Rajiv Indravadan Modi, PhD)
• Inventors: Khamar, Bakulesh Mafatlal, Modi, Rajiv Indravadan, Bansal, Yatish Kumar
• Primary Examiner(s): Naff, David M.
• Assistant Examiner(s): MELLER, MICHAEL V
• Application Number:
  US09/045,890
• Time in Patent Office: 1,310 Days
• Field of Search: 424/93.44, 424/93.45, 435/253.4, 435/252.9
• US Class Current: 424/93.44
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/742 Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• CPC Class Codes: A61K 35/744 Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61K 36/064 Saccharomycetales, e.g. baker's yeast
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer
• CPC Class Codes: A61K 9/2866 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/4808 characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084
• CPC Class Codes: A61K 9/5047 Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Abstract

A process of making a stable fixed dose oral pharmaceutical formulation is provided. The formulation contains at least one anti-infective agent and at least one microorganism. The process involves a step of first coating the agent and/or the microorganism to provide a protective barrier around it. Next, the process involves a step of combining the agent and the microorganism into a single pharmaceutical formulation in the form of a capsule or a tablet. The barrier protects the microorganism from the effect of the anti-infective agent to maintain the microorganism in a viable form for a period of at least three months. The agent can be an antibiotic such as amoxycillin and the microorganism can be Lactobacillus acidophilus.

Claims

1. A process to provide a stable fixed dose oral pharmaceutical formulation comprising at least one anti-infective agent as a first active ingredient and at least one micro organism susceptible to said anti-infective agent as a second active ingredient, the process consisting essentially of a step of coating at least one of the first and second active ingredients to provide a protective barrier around the active ingredient, and thereafter a step of combining the active ingredients into a single pharmaceutical formulation selected from the group consisting of a tablet and a capsule wherein said tablet or capsule contains both said anti-infective agent and said micro organism, the protective barrier protects the susceptible micro-organism from the effect of the anti-infective agent to maintain the susceptible micro-organism in a viable form for a period of at least three months, said anti-infective agent is selected from the group consisting of Ampicillin, Amoxycillin, Cloxacillin, Clavulanic acid, Sultamicin, Cefuroxime axetil, Cefadroxyl, Cephalexin, Cefixime, Erythromycin, Ciprofloxacin, and combinations thereof, and said micro organism is selected from the group consisting of Lactobacillus acidophilus, Lactobacillus spores, Lactobacillus lactis, Streptococcus thermophilus, Streptococcus lactis, Saccromyces cerevisea, Lactobacilli GG, and combinations thereof.

2. A process as claimed in claim 1 wherein the anti-infective agent and the micro organisms are separately admixed with physiologically acceptable excipients.

3. A process as claimed in claim 1 which process comprises admixing separately the anti-infective agent and the micro organism with a physiologically acceptable excipient to provide granules of the anti-infective agent and the micro organism, and coating at least one of the anti-infective agent granules and the micro organism granules, and subsequently compressing said anti-infective agent granules and said micro organisim granules into a layered tablet such that one layer contains the anti-infective agent and the other layer contains the micro organism.

4. A process as claimed in claim 3 wherein the excipient is ethyl cellulose and said coating is performed by suspending the granules to be coated in a suspension containing ethyl cellulose dissolved in isopropyl alcohol and dichloromethane.

5. A process as claimed in claim 4 wherein the excipient is a mixture of microcrystalline cellulose, and starch.

6. A process as claimed in claim 3 wherein the excipient is a mixture of magnesium stearate, polyplasdone XL and sodium chloride.

7. A process as claimed in claim 1 wherein one of the active ingredients is compressed into a tablet and coated, and said coated tablet is put into a capsule containing the other active ingredient.

8. A process as claimed in claim 7 wherein said tablet contains said micro organism admixed with physiologically acceptable excipients.

9. A process as claimed in claim 7 wherein coating to produce the coated tablet is carried out by using a coating suspension comprising hydroxy propyl methyl cellulose phthalate, titanium dioxide, talc, polyethelene glycol, isopropyl alcohol, and dichloro methane.

10. A process as claimed in claim 1 wherein a mixture is formed containing the anti-infective agent and a mixture of physiologically acceptable excipients containing pregelatinised starch, magnesium stearate, and sodium lauryl sulfate, and the mixture containing the anti-infective agent and the excipients is subsequently filled into capsules.

11. A process as claimed in claim 1 wherein coating of the anti-infective agent is carried out by using a coating suspension comprising cellulose acetate phthalate, isopropyl alcohol, and dichloromethane.

12. A process as claimed in claim 1 wherein the anti-infective agent is coated in a coating suspension comprising hydroxy propyl methyl cellulose and purified water.

13. A stable fixed-dose oral pharmaceutical composition prepared by the process of claim 1.

14. The stable pharmaceutical composition of claim 13 wherein the ratio of anti-infective agent to micro organism is in the range of 2:

1 to 25;

1.

15. The stable pharmaceutical composition of claim 14 wherein the ratio of anti-infective agent to micro organism is about 5:

1.

16. The stable pharmaceutical composition of claim 13 wherein the coating comprises a compound selected from the group consisting of cellulose acetate phthalate;

poly(butylmethacrylate, (2-dimethyl aminoethyl) methacrylate, methyl methaacrylate);

poly(ethyl acrylate, methyl methacrylate);

poly(methacrylic acid, methyl methacrylate);

poly(methacrylic acid, ethyl acrylate);

poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride), hydrogenated Castor oil;

Cetyl alcohol;

diethyl phthalate;

ethyl cellulose;

hydroxypropyl cellulose;

hydroxypropyl methylcellulose phthalate; and

zein.